Compare LODE & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | FHTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.0M | 323.4M |
| IPO Year | 2004 | 2020 |
| Metric | LODE | FHTX |
|---|---|---|
| Price | $3.72 | $3.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $4.00 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 1.7M | 142.7K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | $1,553,796.00 | ★ $30,909,000.00 |
| Revenue This Year | $1,582.85 | $8.89 |
| Revenue Next Year | $246.20 | $20.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $2.24 | $3.27 |
| 52 Week High | $4.80 | $6.95 |
| Indicator | LODE | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 42.32 |
| Support Level | $3.48 | $3.59 |
| Resistance Level | $3.75 | $5.84 |
| Average True Range (ATR) | 0.27 | 0.24 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 0.00 | 31.90 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.